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We applied the multi-trait analysis of GWAS 
(MTAG) algorithm to datasets of European 
descent (unless otherwise specified). a, We 
applied MTAG to four datasets (glaucoma case-
control GWAS from the UKBB; GWAS meta-
analysis of intraocular pressure (IOP) from the 
International Glaucoma Genetics Consortium 
(IGGC) and the UKBB; Vertical cup-disc ratio 
(VCDR) GWAS data that was either adjusted for 
vertical disc diameter (VDD) in the UKBB 
dataset; or not adjusted for VDD in the IGGC). 
Novel variants identified through this analysis 
were then confirmed in two independent data 
sets: an Australasian cohort of advanced 
glaucoma (ANZRAG) and a consortium of 
cohorts from the United States 
(NEIGHBORHOOD). The clinical significance of 
the PRS derived from the MTAG analysis was 
validated in independent samples: first, in 
advanced glaucoma cases (ANZRAG and 
samples from Southampton/Liverpool in the 
UK), and second, in a prospectively monitored 
clinical cohort with early manifest glaucoma 
(PROGRESSA). b, Prediction in BMES, where 
we removed the IGGC VCDR and IGGC IOP 
GWAS from the training datasets, given that 
they contain BMES data. c, Prediction in the 
UKBB glaucoma and ICD-10 POAG cases. Here 
we removed all glaucoma cases and 3,000 
controls with IOP/VCDR measurements as well 
as their relatives from UKBB VCDR/IOP GWAS. 
We also evaluated the performance of PRS in 
non-European ancestry (192 cases and 6,841 
controls of South Asian ancestry in UKBB). d, 
Cumulative risk of glaucoma in UKBB. For the 
analysis of MYOC p.Gln368Ter carriers (n = 
965; cases = 72; controls = 893), participants 
were stratified into tertiles of PRS. We also 
examined cumulative risk of glaucoma in the 
general population (i.e. in MYOC p.Gln368Ter 
non-carriers, n = 381,196; cases = 7,381; 
controls = 373,815) stratifying by deciles of the 
PRS. The discovery and testing datasets were 
designed to derive the PRS with no sample 
overlap (Supplementary Note). 
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 89 
Glaucoma, a disease characterized by progressive optic nerve degeneration, can be prevented 90 
through timely diagnosis and treatment. We characterized optic nerve photographs of 67,040 91 
UK Biobank participants and used a multitrait genetic model to identify risk loci for glaucoma. 92 
A novel glaucoma polygenic risk score (PRS) enables effective risk stratification in unselected 93 
glaucoma cases, and modifies penetrance of MYOC p.Gln368Ter, the most common glaucoma-94 
associated myocilin variant. In the unselected glaucoma population, individuals in the top PRS 95 
decile reach an absolute risk for glaucoma 10 years earlier than the bottom decile, and are at 96 
15-fold increased risk of developing advanced glaucoma (top 10% vs. remaining 90% OR = 97 
4.20). The PRS predicts glaucoma progression in prospectively monitored early manifest 98 
glaucoma cases (P = 0.004), and surgical intervention in advanced disease (P = 3.6 × 10-6). This 99 
glaucoma PRS will facilitate the development of a personalized approach for earlier treatment 100 
of high-risk individuals, with less intensive monitoring and treatment possible for lower-risk 101 
groups. 102 
 103 
Glaucoma refers to a group of ocular conditions united by a clinically characteristic optic neuropathy 104 
associated with, but not dependent on, elevated intraocular pressure1. It is the leading cause of 105 
irreversible blindness worldwide and is predicted to affect 76 million by 20202,3. There is no single 106 
definitive biomarker for glaucoma, and diagnosis involves assessing clinical features, with 107 
characterization of the optic nerve head carrying the strongest evidential weight. Primary open-angle 108 
glaucoma (POAG) is the most prevalent subtype of glaucoma in people of European and African 109 
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ancestry2,4. POAG is asymptomatic in the early stages, and currently approximately half of all cases in 110 
the community are undiagnosed even in developed countries5. Early detection is paramount as 111 
existing treatments are unable to restore vision that has been lost, and late presentation is a major 112 
risk factor for blindness6. Thus, better strategies to identify high-risk individuals are urgently needed7, 113 
and more refined approaches can capitalize on the fact that POAG is one of the most heritable of all 114 
common human diseases8–10. The lack of a currently cost-effective screening strategy for glaucoma7, 115 
coupled with very high heritability, make glaucoma an ideal candidate disease for the development 116 
and application of a polygenic risk score to facilitate risk stratification. 117 
Overlap of features shared by healthy optic nerves with those in early stages of glaucoma 118 
makes it a difficult disease to diagnose early, necessitating costly ongoing monitoring of patients for 119 
progressive optic nerve degeneration1. Once a glaucoma diagnosis is established, rates of 120 
progression vary widely between individuals, and considerable time can elapse before surveillance 121 
techniques adequately differentiate slow from more rapidly progressing cases1. Progressive vision 122 
loss from glaucoma can be slowed, or in some cases halted, by timely intervention to reduce 123 
intraocular pressure using medical therapy, laser trabeculoplasty or incisional surgery1. The ability to 124 
predict progression is currently crude, with delays in treatment escalation for high-risk individuals an 125 
important and inevitable consequence, as well as substantial cost and morbidity associated with 126 
overtreatment of lower risk cases.  127 
The chronicity, heritability, clinical heterogeneity and treatability of POAG make it an ideal 128 
candidate for genetic risk profiling11,12. In this study, we evaluated the optic nerve head in 67,040 UK 129 
Biobank participants (UKBB), enabling the largest genome-wide association study (GWAS) on optic 130 
nerve morphology to date, using vertical cup-disc ratio (VCDR) as an endophenotype for glaucoma. 131 
We then incorporated additional genetic data from a second well established glaucoma 132 
endophenotype, intraocular pressure (IOP), and combined this with glaucoma disease status using a 133 
recently developed multiple trait analysis of GWAS (MTAG)13 approach to first identify new risk loci for 134 
glaucoma, and then generate a comprehensive glaucoma polygenic risk score (PRS). We examined 135 
the impact of newly implicated glaucoma genes in independent case-control cohorts from Australia, 136 
the United States, and the United Kingdom, and then evaluated the utility of the PRS for predicting 137 






Study design. Our overall study design is illustrated in Extended Data Figure 1a. We first conducted 142 
a GWAS on glaucoma (7,947 cases and 119,318 controls) and on the key endophenotypes for 143 
glaucoma: VCDR (including new data on 67,040 UKBB participants, and International Glaucoma 144 
Genetics Consortium, IGGC, n = 23,899) and intraocular pressure (including data on 103,914 UKBB 145 
participants and GWAS summary statistics from IGGC, n = 29,578; Supplementary Table 1). These 146 
data were then combined using MTAG13 to identify new glaucoma risk loci and to construct a PRS. 147 
The clinical significance of the PRS was investigated in advanced glaucoma cases in two populations, 148 
and a separate prospectively monitored clinical cohort with early manifest glaucoma. The predictive 149 
ability of the PRS was also explored in other datasets; however, to ensure our results generalize to 150 
further cohorts, we selected mutually exclusive samples for inclusion in the discovery and testing 151 
datasets to ensure no sample overlap. When required, we re-derived the PRS to ensure no sample 152 
overlap (Extended Data Fig. 1b-d and Supplementary Note).  153 
 154 
Discovery of novel optic nerve morphology loci. GWAS of VCDR (adjusted for vertical disc 155 
diameter) identified 76 statistically independent, genome-wide significant SNPs (66 loci), of which 49 156 
SNPs (43 loci) had not previously been associated with VCDR (Supplementary Figs. 1 and 2, and 157 
Supplementary Table 2). Using LD score regression, we found no evidence for genomic inflation 158 
(intercept = 1.04, s.e. = 0.01, Supplementary Fig. 3). The genetic correlation between VCDR 159 
(adjusted for vertical disc diameter) and glaucoma in UKBB was 0.50 (s.e. = 0.05); the correlation in 160 
effect size estimates at the 76 SNPs was 0.60 (P = 9.0 × 10-9, Supplementary Fig. 4). We further 161 
combined UKBB VCDR (adjusted for vertical disc diameter) GWAS and IGGC VCDR GWAS 162 
summary statistics using MTAG, and identified 107 independent genome-wide significant SNPs 163 
(across 90 loci, Supplementary Table 3) for VCDR (adjusted for vertical disc diameter). As previously 164 
reported, the genetic correlation between intraocular pressure and glaucoma was high (0.71)15, but as 165 
expected the genetic correlation between VCDR (adjusted for vertical disc diameter) and intraocular 166 




Discovery of novel glaucoma loci via multivariate analysis. Given the high correlation between 169 
glaucoma and its endophenotypes, we then conducted a multivariate GWAS (with 8,002,429 SNPs 170 
after quality control) to identify 114 statistically independent SNPs (107 loci, P < 5 × 10-8) associated 171 
with glaucoma; this includes all previously published glaucoma loci as well as 49 novel loci (Fig. 1, 172 
Supplementary Figs. 5 and 6, and Supplementary Table 4). At the more stringent multiple testing 173 
threshold (P < 1 × 10-8) suggested by a simulation study16, 95 loci reach significance, 39 of which are 174 
novel (Supplementary Table 4); 27 of the 49 top SNPs at these novel loci were not associated 175 
individually with any of the individual input traits at the genome-wide significance level (P = 5 × 10-8) 176 
and were only found to reach this threshold for glaucoma due to the MTAG method leveraging the 177 
strong correlation between the input traits. We then attempted to replicate the 49 novel SNPs in two 178 
independent glaucoma cohorts (ANZRAG and NEIGHBORHOOD). Given the much smaller effective 179 
sample size of these replication cohorts (versus the discovery datasets from the MTAG analysis), we 180 
did not expect all of the SNPs to be strongly associated; rather, if they were genuine associations, we 181 
would expect the ORs to be highly concordant, with some of the smaller ORs being individually non-182 
significant. The concordance between the discovery cohort and our replication cohorts log ORs was 183 
excellent (correlation 0.88, P = 1.6 × 10-36), indicating that our multivariate model was successful in 184 
identifying genuine glaucoma risk loci (Fig. 2 and Supplementary Fig. 7). Of the 49 novel SNPs, nine 185 
were replicated after Bonferroni correction (P < 0.05/49 = 0.001, one-sided test, bold text in 186 
Supplementary Table 4), 26 were associated at a nominal significance level (P < 0.05, one-sided test, 187 
italic text in Supplementary Table 4), and 46 (94%) were in the expected direction. While the 188 
concordance between the multivariate and the glaucoma replication sample log ORs was high, only 189 
nine of the 49 loci were significant for glaucoma after correction for multiple comparisons, and further 190 
studies are required to replicate the remaining 40 loci for glaucoma.  191 
We conducted a genome-wide gene-based association analysis and a gene set enrichment 192 
analysis to assess which predefined biological pathways were enriched in our multitrait glaucoma 193 
GWAS; we found 196 genes and 14 gene sets, respectively, that were significant after Bonferroni 194 
correction (Supplementary Tables 5 and 6). The most significant pathways were also previously 195 
implicated (i.e. extracellular matrix, collagen, and circulatory system development)15,17. Further studies 196 




Optimizing prediction of glaucoma risk by combining correlated traits. We derived our PRS 199 
based on the MTAG of GWAS data from glaucoma and its endophenotypes. As well as increasing the 200 
number of SNPs that reach genome-wide significance (mean chi-squared statistic increased from 201 
1.12 to 1.30, implying our effective sample size was 2.59 times larger than if we had used UKBB 202 
glaucoma cases and controls alone), our multivariate model improved the power of risk prediction by 203 
reducing the error in the estimate of the effect size for every SNP (assuming the MTAG homogeneity 204 
assumption is true, see Discussion)13. We first tested the discriminatory power of the MTAG-derived 205 
PRS in the ANZRAG cohort of advanced glaucoma. We found SNPs with MTAG P values ≤ 0.001 206 
(corresponding to 2,673 uncorrelated SNPs after LD-clumping at r2 = 0.1 and P-value threshold at 207 
0.001) had the highest Nagelkerke R2 (13.2%) and AUC (0.68, 95%CI: 0.67-0.70) (Supplementary 208 
Table 7). The MTAG PRS has better prediction ability than any of the input traits alone 209 
(Supplementary Table 8). Based on this, we set the P-value threshold at 0.001 for all the remaining 210 
prediction target sets (PROGRESSA, BMES, UKBB).  211 
The MTAG-derived PRS was effective at separating advanced glaucoma individuals in terms 212 
of risk, with a clear dose-response over deciles (Fig. 3a and Supplementary Fig. 8). In ANZRAG, 213 
individuals in the top decile of the PRS had 14.9-fold higher risk (95%CI: 10.7-20.9) relative to the 214 
bottom decile, with even better discrimination for the more common high-tension glaucoma (OR = 215 
21.5, 95%CI: 12.5-37.0) than normal-tension glaucoma (Supplementary Fig. 9). We replicated the 216 
dose-response of the PRS in a smaller UK advanced glaucoma dataset (Southampton and Liverpool); 217 
the top versus bottom PRS decile had OR = 11.6 (95%CI: 6.0-25.3), with again better discrimination 218 
for high-tension glaucoma (OR = 12.9, 95%CI: 6.2-31.3). While comparing the top and bottom deciles 219 
shows the dose-response across deciles, one can also consider the risk in the high PRS individuals 220 
versus all others; when this is done in ANZRAG, the OR is 4.2 and 8.5 in the top 10% and 1%, 221 
respectively, of individuals versus all remaining individuals (Supplementary Table 9).   222 
 223 
Glaucoma risk score performance in individuals carrying high penetrance variants. Previous 224 
studies indicated that PRS modifies the penetrance of rare BRCA1/2 mutation carriers for breast, 225 
ovarian, and prostate cancers18,19. Although the MTAG-derived PRS only contains common variants, 226 
given it indexes general glaucoma risk, we hypothesized that it could stratify individuals carrying 227 
known high-penetrance glaucoma variants. Pathogenic MYOC (Myocilin) gene variants account for 2-228 
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4% of POAG cases among most populations, the most common disease-causing variant being 229 
p.Gln368Ter (rs74315329)20. Penetrance is age-related and is lower in population-based than family-230 
based studies20,21. We speculated that this difference in penetrance could be due to enrichment of 231 
common glaucoma-associated variants in families modifying age-related penetrance. Within UKBB, 232 
we identified 965 MYOC p.Gln368Ter carriers based on imputation (Supplementary Note)22. Figure 3c 233 
shows the cumulative risk of glaucoma in p.Gln368Ter carriers, stratifying by PRS tertiles. For 234 
p.Gln368Ter carriers in the lowest tertile PRS, glaucoma risk remained very low (2%) up to age 60. In 235 
contrast, the highest tertile PRS group had substantially increased risk of early diagnosis, reaching a 236 
6-fold increase in absolute risk of glaucoma by age 60, relative to the lowest PRS tertile (considering 237 
whole age range, hazard ratio = 3.4, 95%CI: 1.7-6.6). This supports the utility of PRS in optimizing 238 
risk stratification and prediction, and early screening for patients carrying high penetrance MYOC 239 
variants in the presence of high PRS scores. 240 
 241 
Potential for glaucoma risk score in screening in the general population. We considered a 242 
general population screening scenario using UKBB (PRS was re-derived to ensure no sample 243 
overlap; Extended Data Fig. 1d), where we excluded the 965 MYOC p.Gln368Ter carriers. Over the 244 
40-69 year old age range for individuals sampled in UKBB, glaucoma prevalence increases from 245 
0.1% at age 40, reaching 3% (95%CI: 2.9-3.1%) by age 64. The MTAG-derived PRS stratifies UKBB 246 
participants very effectively; for those in the top PRS decile, 3% prevalence (prevalence in general 247 
population) is reached by age 59, while it takes an additional 10 years for this disease prevalence to 248 
be reached for people in the bottom PRS decile. Alternatively, the prevalence can be well stratified by 249 
PRS deciles (Fig. 3d).  250 
To benchmark the performance of the MTAG-derived PRS with traditional risk factors, we 251 
computed the AUC in datasets for which this was possible: BMES, UKBB glaucoma (broad glaucoma 252 
definition), and UKBB POAG (ICD-10 definition) (Fig. 3b, Supplementary Table 11 (PRS was re-253 
derived to ensure no sample overlap), and Extended Data Fig. 1). In the BMES, our PRS provided 254 
additional predictive ability beyond that imparted by traditional risk factors (age, sex, and self-reported 255 
family history (FH)), with a significant change in the AUC (from 0.73 to 0.80, P = 0.002, Fig. 3b). Clear 256 
improvement in prediction using this PRS is also observed in people of South Asian ancestry 257 
(Supplementary Table 11), though we were underpowered to explore this further across other groups.  258 
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A previous study examined the cost-effectiveness requirements for glaucoma screening and 259 
highlighted the key age 50-60 bracket7. In the BMES data (Extended Data Fig. 1b), screening only 260 
those with a top decile PRS identified 40% of all early onset cases in age 50-60 bracket (40% of the 261 
10 cases, P = 0.013). Such individuals represent a set of individuals likely to benefit from referral for 262 
immediate clinical assessment—with skilled clinical examination, retinal imaging, and visual fields. We 263 
replicated this result in the UKBB POAG cohort (ICD10 cases in Extended Data Fig. 1c, top 10% PRS 264 
screening finds 29% of 24 cases aged 50-60, P = 0.0075). In this way, PRS-based screening would 265 
satisfy the cost-effectiveness requirements of Burr et al.7, identify a meaningful proportion of cases, 266 
and capture those cases most at risk of severe disease.  267 
 268 
Clinical implications of the glaucoma risk score. We evaluated the predictive power of the PRS in 269 
advanced glaucoma; in 1,336 ANZRAG advanced POAG cases with accurate age at diagnosis 270 
information available (Supplementary Table 12), the PRS was significantly associated with age at 271 
diagnosis of POAG (P = 1.8 × 10-5). Individuals in the top 10% of the PRS distribution were on 272 
average diagnosed 7 years younger than people in the bottom 10% (Fig. 4a). We also found 273 
ANZRAG individuals with higher PRS had more family members affected by glaucoma (P = 3.5 × 10-274 
9), with the highest decile having twice as many members affected (Supplementary Fig. 10). 275 
Retinal nerve fibre layer thinning is a major structural change evident in early stage 276 
glaucoma23. In the early manifest glaucoma (PROGRESSA) cohort, the PRS predicted both the 277 
proportion lost and rate of loss of peripapillary retinal nerve fibre layer. Given that glaucomatous loss 278 
of retinal ganglion cells generally progresses unequally between eyes, with some quadrants of the 279 
retina damaged more rapidly than others, we analyzed the most affected quadrant of the most 280 
affected eye in individuals with early manifest glaucoma and greater than two years of longitudinal 281 
optical coherence tomography data. The PRS was significantly associated with the proportion of 282 
retinal nerve fibre layer lost from baseline to most recent review, even after adjustment for known risk 283 
factors: age, intraocular pressure and retinal nerve fibre layer thickness at presentation (P = 0.004; 284 
Fig. 4b and Supplementary Table 13). Expressed in terms of rate of loss, each decile change in PRS 285 
was associated with an accelerated progression rate of 0.05 µm/year, which was twice the rate of 286 
thinning per mmHg (approximately 1 decile change for intraocular pressure) of baseline intraocular 287 
pressure (0.022 µm/year). 288 
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Incisional surgery for glaucoma (trabeculectomy) is highly effective at reducing intraocular 289 
pressure, but has significant complications which can adversely impact vision1. Trabeculectomy is 290 
performed either when intraocular pressure is unable to be controlled with medical or laser therapy, or 291 
when there is progressive visual field loss despite well controlled intraocular pressure. Patients with a 292 
high PRS were more likely to have undergone surgery for glaucoma (Fig. 4c and Supplementary 293 
Figure 11). In the ANZRAG cohort of POAG cases, a higher PRS was associated with requiring 294 
trabeculectomy, even after adjustment for maximum recorded intraocular pressure and age (P = 3.6 × 295 
10-6), the OR of requiring trabeculectomy in either eye for people in the top PRS decile was 1.78 296 
(95%CI: 1.07–3.00) compared to the bottom decile. We observed a very similar trend in our UK 297 
replication (Southampton/Liverpool) samples (Supplementary Fig. 11).  298 
 299 
Discussion 300 
Through a large-scale multivariate GWAS we identified novel genes for glaucoma, the leading cause 301 
of irreversible blindness worldwide2. Despite a smaller replication cohort, many of these novel hits 302 
were replicated, and all but three SNPs showed a consistent direction of effect. We then expanded 303 
this analysis to derive a PRS and interrogated its utility across a wide spectrum of clinically relevant 304 
glaucoma outcomes.  305 
From the multivariate GWAS, we identified 49 novel loci associated with glaucoma (nine of 306 
which replicated after correction for multiple comparisons in independent glaucoma case-control 307 
cohorts; 26 were replicated with P < 0.05). Interestingly, most of the loci replicated at P < 0.001 are at 308 
genes previously associated with glaucoma risk factors (myopia, CCT, IOP, VCDR). Specifically, 309 
RSPO1 is associated with ocular axial length24. BICC1 is associated with myopia and corneal 310 
astigmatism25,26,27. POU6F2 modulates corneal thickness and increases glaucoma risk in animal 311 
experiments28. FBXO32, PTPN1, and VPS13C are associated with IOP15,29,30, while CASC20 was 312 
identified in our VCDR (adjusted for vertical disc diameter) GWAS. These findings show that our 313 
multivariate GWAS improves power to identify novel glaucoma genes and advance our understanding 314 
of the causes of glaucoma risk. 315 
The MTAG-derived PRS was validated in independent samples, confirming its high predictive 316 
ability. Individuals in the top PRS decile were at 15-fold increased risk of advanced glaucoma, and at 317 
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21.5-fold increased risk of advanced high tension glaucoma, relative to the bottom decile, which 318 
represents a substantial improvement on previously reported genetic profiling strategies (where, 319 
based on SNPs that were genome-wide significantly associated with intraocular pressure and SNPs 320 
previously associated with VCDR and glaucoma, top decile individuals had a 5.6-fold increased 321 
risk)15. This new glaucoma PRS also outperforms those derived from other well-studied conditions; for 322 
example, our OR comparing the top 1% PRS individuals versus the remaining individuals was 8.5, 323 
which is higher than that seen in a recent study which surveyed coronary artery, atrial fibrillation, type 324 
2 diabetes, inflammatory bowel disease and breast cancer31. The etiology of complex diseases 325 
depends on both environmental and genetic factors; thus, PRS alone will never achieve the very high 326 
predictive power (e.g. AUC > 0.99) required for accurate population screening32. Our glaucoma PRS 327 
will be primarily useful for stratifying individuals into risk groups; for example in the BMES data, 328 
screening the top decile of the PRS in individuals between 50-60 years old identifies 40% of cases. 329 
Moreover, as argued by Khera et al.31, individuals with a high PRS for glaucoma are likely to be at a 330 
similar risk to individuals carrying rare “high penetrance” MYOC mutations21. Finally, the PRS 331 
performance for glaucoma is particularly noteworthy given the clinical implications of identifying at-risk 332 
individuals and the prevention of irreversible blindness with readily available treatment proven to be 333 
effective at preventing visual loss. 334 
While current treatments are effective in preventing or reducing POAG progression12, many 335 
patients are not diagnosed before irreversible damage to visual function has already occurred. Earlier 336 
diagnosis of glaucoma can reduce glaucoma blindness, and our work demonstrates that people with a 337 
higher PRS require earlier clinical assessment. In the UKBB, individuals in the top PRS decile reach 338 
an equivalent absolute risk for glaucoma 10 years earlier than people in the bottom decile. In 339 
advanced glaucoma cases, individuals in the top decile were diagnosed 7 years earlier than those in 340 
the bottom decile. Similarly, the MTAG-derived PRS was associated with significantly earlier disease 341 
onset in UK Biobank MYOC p.Gln368Ter carriers who are at high disease risk. The MTAG-derived 342 
PRS can also identify people with early manifest glaucoma who are at higher probability of disease 343 
progression, as well as the likelihood of requiring surgical intervention, which is highly effective at 344 
reducing intraocular pressure, but carries substantial treatment morbidity meaning it should always be 345 
targeted specifically to those at higher risk of disease progression and blindness. 346 
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A concern with the MTAG method is the homogeneous assumption, which could be violated 347 
for some SNPs that have no effect on one trait but are non-null for other traits (i.e. it is possible that a 348 
small number of the variants may be more specific for IOP or VCDR rather than glaucoma). The 349 
homogeneity assumption has been studied in detail by Turley et al.13 We have evaluated the possible 350 
inflation using max False Discovery Rate (maxFDR) as recommended13. The baseline maxFDR for 351 
MTAG glaucoma-specific input GWAS summary statistics is 0.049, and the maxFDR for MTAG 352 
glaucoma-specific output summary statistics is 0.03. As these are similar, there is no evidence of 353 
inflation due to violation of the homogeneity assumption. As recommended by the MTAG authors, we 354 
also performed replication analysis to assess the credibility of novel SNPs in two independent data 355 
sets (an Australasian cohort of advanced glaucoma (ANZRAG) and a consortium of cohorts from the 356 
United States (NEIGHBORHOOD)); this analysis shows there is very good concordance between the 357 
MTAG-based effect sizes and those from the glaucoma cohorts. Furthermore, using MTAG output 358 
instead of the individual input traits improves the predictions in independent cohorts (Supplementary 359 
Table 8), providing additional evidence that we are not merely identifying IOP- or VCDR-specific loci 360 
that have no effect on glaucoma. Further research needs to be undertaken to investigate the 361 
biological mechanisms of these novel genes on glaucoma risk.  362 
A limitation of this work, is that in our 7,947 UKBB glaucoma cases, only a small proportion 363 
had documented disease subtype; however, since the proportion of UK glaucoma cases that have 364 
POAG is high (87% in a recent study4), this is unlikely to have a large influence on our results. A 365 
further limitation is that it is not yet clear how applicable our findings are to other populations. We 366 
showed that the PRS improved prediction accuracy over and above traditional risk factors in 367 
homogeneous groups (as defined by genetic principal components) of either European or South 368 
Asian ancestry. The performance of the PRS in other populations should be tested to investigate the 369 
generalizability of our findings. The performance of the PRS in aiding clinical decision making and 370 
guiding earlier treatment could be evaluated prospectively in a longitudinal intervention study, with 371 
participants randomized to have their PRS provided or withheld from their treating specialist.  372 
In summary, we have applied a multivariate approach using weighted data on glaucoma, and 373 
endophenotypes intraocular pressure and VCDR, to identify novel glaucoma loci, and develop a 374 
polygenic risk score. This PRS was shown to be predictive of: 1) increasing risk of advanced 375 
glaucoma; 2) glaucoma status significantly beyond traditional risk factors; 3) earlier age of glaucoma 376 
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diagnosis; 4) high levels of absolute risk in persons carrying high penetrance glaucoma variants; 5) 377 
increasing likelihood of disease progression in early stage disease, and 6) increasing likelihood of 378 
incisional glaucoma surgery in advanced disease. This glaucoma PRS has good predictive power 379 
across a range of clinical cohorts and its application will facilitate the rational allocation of resources 380 
through clinical screening and timely treatment in high-risk patients, with reduced clinical monitoring 381 
costs in lower risk groups. 382 
 383 
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Figure Legends: 493 
Figure 1 | Manhattan plot displaying glaucoma-specific P values from the multi-trait GWAS 494 
(MTAG) analysis. The samples used in multi-trait analysis is presented in Extended Data Figure1a. Novel 495 
SNPs are highlighted in red dots, with the nearest gene names in black text. Known SNPs are highlighted in 496 
purple dots, with the nearest gene names in purple text. The red line  is the genome-wide significance level at 5 × 497 
10-8. 498 
 499 
Figure 2 | Comparison of the effect sizes (log odds ratio) for 114 genome-wide significant 500 
independent SNPs identified from the glaucoma multiple trait analysis of GWAS in the UKBB 501 
versus those in independent glaucoma cohorts (meta-analysis of ANZRAG and 502 
NEIGHBORHOOD). Pearson’s correlation coefficient is 0.88 (P = 1.6 × 10-36). The red line is the best fit line, 503 
with the 95% confidence interval region in grey. Novel glaucoma SNPs are highlighted in red and known SNPs in 504 
purple. 505 
 506 
Figure 3 | Multiple trait analysis of GWAS PRS prediction. a, Odds ratio (OR) of developing advanced 507 
glaucoma in the ANZRAG cohort (with 1,734 advanced glaucoma cases and 2,938 controls) for each PRS decile. 508 
The square dots are the OR values (adjusted for sex and the first four principal components) and the error bars 509 
are 95% confidence interval. The dashed line is the reference at the bottom PRS decile (OR = 1). b, AUCs of 510 
PRS in BMES. The MTAG-derived PRS provided additional predictive ability on top of traditional risk factors (age, 511 
sex, and self-reported family history (FH), DeLong's test P = 0.002). The AUC is based on a logistic regression 512 
model with the coefficients for age, sex, FH and PRS estimated from the BMES data (Supplementary Table 10). 513 
c, Cumulative risk of glaucoma in UKBB MYOC p.Gln368Ter carriers stratifying by the PRS (adjusted for sex and 514 
first six genetic principal components). Here the cumulative risk of tertiles (with 95% confidence intervals) of PRS 515 
are displayed given the relatively small number of MYOC p.Gln368Ter carriers (n = 965). d, Cumulative risk of 516 
glaucoma for people in the top and bottom decile (with 95% confidence intervals) of PRS of the UKBB who do not 517 
have the MYOC p.Gln368Ter variant (adjusted for sex and first six genetic principal components). The dashed 518 
line is the reference line of cumulative risk at 3%.  519 
 520 
Figure 4 | Clinical implications of the glaucoma PRS. a, Mean age at diagnosis (years) for each decile 521 
of PRS in the ANZRAG cohort (linear regression P = 1.8 × 10-5). A total of 1,336 cases had accurate age at 522 
diagnosis information. We calculated the mean age at diagnosis for each decile of PRS, adjusted for sex and the 523 
first four principal components in a linear regression model. The square dots are the regression-based mean age 524 
at diagnosis, with error bars for 95% confidence intervals. The red line is the line of best fit, with 95% confidence 525 
intervals in grey. b, Proportion of preserved baseline retinal nerve fibre layer for PROGRESSA participants with 526 
early manifest glaucoma plotted against PRS decile (n = 388; linear regression P = 0.004). The square dots are 527 
the retinal nerve fibre layer proportions, with error bars showing 95% confidence intervals. The remaining retinal 528 
nerve fibre layer proportion is calculated for the most affected quadrant of the most affected eye of each patient 529 
— as determined on optical coherence tomography scans at baseline and latest follow-up scan. c, Proportion of 530 
patients requiring trabeculectomy in either eye in the ANZRAG POAG cohort (linear regression P = 3.6 × 10-6). 531 
There were 1,360 cases with records of surgical treatment status. The square dots represent the observed 532 
average proportion of cases in each decile of PRS who required trabeculectomy, with 95% confidence interval 533 
bars. The line of best fit is shown in red, with 95% confidence interval shaded in grey.  534 




Study design and overview. Our overall study design is illustrated in Extended Data Figure 1. We 537 
first conducted a GWAS on glaucoma and on the key endophenotypes for glaucoma: VCDR and 538 
intraocular pressure. These data were then combined using MTAG13, a method for combining multiple 539 
genetically correlated traits to maximize power for identifying new loci and improving genetic risk 540 
prediction. Specifically, our MTAG analysis outputs glaucoma-specific effect size estimates and P-541 
values for single nucleotide polymorphisms (SNPs) across the genome. Newly associated loci (P < 5 542 
× 10-8) were validated in two independent cohorts with well-characterised POAG. We created a PRS 543 
based on the MTAG GWAS summary statistics. The clinical significance of the PRS was investigated 544 
in advanced glaucoma cases in two populations, and a separate prospectively monitored clinical 545 
cohort with early manifest glaucoma. The predictive ability of the PRS was also explored in other 546 
datasets; however, to ensure our results generalize to further cohorts, we selected mutually exclusive 547 
samples for inclusion in the discovery and testing datasets to ensure no sample overlap. When 548 
required, we re-derived the PRS to avoid any sample overlap (Extended Data Fig. 1). Study 549 
procedures were performed in accordance with the World Medical Association Declaration of Helsinki 550 
ethical principles for medical research.  551 
 552 
Study populations. Detailed information of individual studies, phenotypic definitions, and genetic 553 
quality control procedures are provided in the Supplementary Note. 554 
The UK Biobank (UKBB) is a population-based study of half a million people living in the 555 
United Kingdom33. We measured VCDR and vertical disc diameter in all subjects with gradable retinal 556 
images (67,040 participants following exclusions, detailed in Supplementary Note) and undertook a 557 
GWAS to identify SNPs influencing optic nerve head morphology. Vertical disc diameter adjustment of 558 
the VCDR was used to account for optic cup and disc size covariation14,34. To improve power in the 559 
multi-trait analysis, we combined the VCDR data with data on corneal-compensated intraocular 560 
pressure (103,914 participants) and glaucoma (7,947 cases, 119,318 controls) in the MTAG 561 
analysis15. We also used publicly available VCDR and intraocular pressure GWAS summary results 562 
for individuals of European descent from the International Glaucoma Genetics Consortium (IGGC; 563 
nVCDR = 23,899, nintraocular pressure = 29,578)
35.  564 
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The Australian & New Zealand Registry of Advanced Glaucoma (ANZRAG) comprises 3,071 565 
POAG cases of European descent, who were compared to 6,750 controls36,37. For sub-analyses 566 
restricted to advanced POAG, there were 1,734 advanced POAG cases and 2,938 controls, and of 567 
these cases 1,336 participants had accurate age at diagnosis information available. Replication of the 568 
ANZRAG findings was performed using 332 advanced glaucoma cases from Southampton and 569 
Liverpool in the United Kingdom; for case-control analysis, cases were matched to 3,000 randomly 570 
selected European ancestry individuals from the QSkin Sun and Health study38. The National Eye 571 
Institute Glaucoma Human Genetics Collaboration Heritable Overall Operational Database 572 
(NEIGHBORHOOD) GWAS results were generated through meta-analyzing summary data from eight 573 
independent datasets (3,853 POAG cases, 33,480 controls) of European ancestry from the United 574 
States39.  575 
The Blue Mountains Eye Study (BMES) is a population-based cohort study investigating the 576 
etiology of common ocular diseases among suburban residents aged 49 years or older in Australia5. 577 
Data from 74 POAG cases and 1,721 controls of European descent with genotype information were 578 
included. 579 
The Progression Risk Of Glaucoma: RElevant SNPs with Significant Association 580 
(PROGRESSA) study is a prospective longitudinal study of the clinical and genetic risk factors, and 581 
course of early-stage glaucoma (n = 388). Patients with confirmed early manifest POAG on sequential 582 
automated perimetry testing were consecutively recruited from ophthalmology clinics in South 583 
Australia (detailed criteria in Supplementary Note). Individuals underwent six-monthly evaluation of 584 
intraocular pressure, optic disc assessment, retinal nerve fibre layer analysis by optical coherence 585 
tomography, and achromatic Humphrey visual field perimetry. Longitudinal data were used from all 586 
visits since baseline presentation; participants were followed for one to eight years. The change in 587 
retinal nerve fibre layer was measured between the baseline optical coherence tomography and the 588 
most recent scan in the most-affected quadrant of the most-affected eye. Treating clinicians and 589 
graders were unaware of the patient’s genetic risk for glaucoma or any PRS data.  590 
POAG in the ANZRAG, NEIGHBORHOOD, BMES, and PROGRESSA cohorts was defined 591 
as outlined previously40, and in accordance with the consensus statement from the World Glaucoma 592 




Statistical analysis. Detailed information on the statistical analysis is provided in the Supplementary 595 
Note. 596 
For the VCDR (adjusted for vertical disc diameter) and intraocular pressure GWAS in UKBB, 597 
we used linear mixed models (BOLT-LMM software) to account for cryptic relatedness and population 598 
stratification adjusting for sex, age and the first ten principal components42. We meta-analyzed UKBB 599 
intraocular pressure GWAS results with those from the IGGC using the inverse variance weighted 600 
method (METAL software) 43. For the UKBB glaucoma GWAS, we removed relatives (pi-hat > 0.2 601 
calculated using identity by descent determined based on autosomal markers) and used PLINK 602 
software for association analysis44.  603 
We then conducted a multitrait GWAS using the MTAG (version 1.0.7) software to combine 604 
the European descent GWAS summary statistics from UKBB glaucoma, UKBB VCDR (adjusted for 605 
vertical disc diameter), IGGC VCDR and the intraocular pressure meta-analysis (Extended Data Fig. 606 
1)13. MTAG performs joint analysis of GWAS summary results from related traits to improve statistical 607 
power to identify new genes and to maximize the predictive ability of our polygenic risk scores13. In 608 
MTAG, GWAS summary results from related traits are used to construct the variance–covariance 609 
matrix of their SNP effects and estimation error; MTAG improves the accuracy of effect estimates by 610 
incorporating information from other genetic correlated traits. The MTAG method explicitly models 611 
sample overlap in the input studies and provides valid estimates even when sample overlap is 612 
present13. To benchmark the increase in effective sample size relative to just using UKBB glaucoma, 613 
we calculated (	 2MTAG – 1) / (	 2GWAS – 1), where 	 2MTAG and 	 2GWAS are the mean chi-614 
squared statistics from MTAG and the UKBB glaucoma analyses, respectively13.  615 
We used a stepwise model selection procedure in the GCTA-COJO software to identify 616 
independent genome-wide significant SNPs45. Gene-based and pathway analysis were conducted in 617 
MAGMA (v1.06), as implemented in FUMA (version 1.3.1)46,47.  618 
Prediction was based on the estimated glaucoma odds ratios (OR) from the MTAG analysis. 619 
To derive a PRS, we considered a range of P-value thresholds (5 × 10-8, 1 × 10-5, 0.001, 0.05, 1) with 620 
LD-clumping r2 = 0.1 for inclusion of SNPs in the prediction model, applying each to our first prediction 621 
cohort (advanced glaucoma from ANZRAG). To avoid falsely inflating prediction accuracy, we applied 622 
the threshold with greatest predictive value in ANZRAG (P ≤ 0.001) for the subsequent predictions 623 
into other target sets (rather than repeatedly taking the best P-value threshold for each of the 624 
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datasets). We tested the LDpred48 approach for PRS construction although the predictions were no 625 
better than those from the thresholding approach described above. There was no sample overlap 626 
between any of the training and target datasets (Extended Data Fig. 1).  627 
Bivariate LD score regression was used to estimate the genetic correlation between pairs of 628 
traits49. The “pROC” package was used to calculate the area under the curve (AUC)50. Analyses were 629 
performed with R software51.  630 
 631 
Data availability. 632 
UK Biobank data are available through the UK Biobank Access Management System 633 
https://www.ukbiobank.ac.uk/. GWAS summary statistics from the glaucoma MTAG analysis are 634 
available for research uses at URL (https://doi.org/10.6084/m9.figshare.10635854 ) after publication. 635 
We will return the derived data fields following the UK biobank policy and in due course they will be 636 
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Top decile PRS & non−MYOC p.Gln368Ter
Bottom decile PRS & non−MYOC p.Gln368Ter
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